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A bs tr ac t
Background 
Selective digestive tract decontamination (SDD) and selective oropharyngeal decon-
tamination (SOD) are infection-prevention measures used in the treatment of some 
patients in intensive care, but reported effects on patient outcome are conflicting.
Methods 
We evaluated the effectiveness of SDD and SOD in a crossover study using cluster 
randomization in 13 intensive care units (ICUs), all in the Netherlands. Patients with 
an expected duration of intubation of more than 48 hours or an expected ICU stay of 
more than 72 hours were eligible. In each ICU, three regimens (SDD, SOD, and stan-
dard care) were applied in random order over the course of 6 months. Mortality at day 
28 was the primary end point. SDD consisted of 4 days of intravenous cefotaxime and 
topical application of tobramycin, colistin, and amphotericin B in the oropharynx and 
stomach. SOD consisted of oropharyngeal application only of the same antibiotics. 
Monthly point-prevalence studies were performed to analyze antibiotic resistance.
Results 
A total of 5939 patients were enrolled in the study, with 1990 assigned to standard care, 
1904 to SOD, and 2045 to SDD; crude mortality in the groups at day 28 was 27.5%, 
26.6%, and 26.9%, respectively. In a random-effects logistic-regression model with age, 
sex, Acute Physiology and Chronic Health Evaluation (APACHE II) score, intubation 
status, and medical specialty used as covariates, odds ratios for death at day 28 in the 
SOD and SDD groups, as compared with the standard-care group, were 0.86 (95% con-
fidence interval [CI], 0.74 to 0.99) and 0.83 (95% CI, 0.72 to 0.97), respectively.
Conclusions 
In an ICU population in which the mortality rate associated with standard care 
was 27.5% at day 28, the rate was reduced by an estimated 3.5 percentage points 
with SDD and by 2.9 percentage points with SOD. (Controlled Clinical Trials num-
ber, ISRCTN35176830.)
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Infections acquired in the intensive care unit (ICU) are important complications of the treatment of critically ill patients, in-
creasing morbidity, mortality, and health care 
costs.1 Reductions in the incidence of respiratory 
tract infections have been achieved with the use 
of prophylactic antibiotic regimens, such as se-
lective decontamination of the digestive tract 
(SDD)2,3 and selective oropharyngeal decontam-
ination (SOD).4,5
The SDD approach6,7 consists of prevention of 
secondary colonization with gram-negative bacte-
ria, Staphylococcus aureus, and yeasts through appli-
cation of nonabsorbable antimicrobial agents in 
the oropharynx and gastrointestinal tract, preemp-
tive treatment of possible infections with commen-
sal respiratory tract bacteria through systemic 
administration of cephalosporins during the pa-
tient’s first 4 days in the ICU, and maintenance of 
anaerobic intestinal flora through selective use 
of antibiotics (administered both topically and 
systemically) without antianaerobic activity.7 De-
spite the beneficial effects of SDD on infection 
rates, most studies have lacked sufficient statis-
tical power to detect effects on survival. In meta-
analyses and in three single-center, randomized 
studies, the use of SDD, including a short course 
of systemic antibiotics, was associated with im-
proved survival.2,3,8-10
SOD (application of topical antibiotics in the 
oropharynx only) has been postulated as an al-
ternative to SDD for the prevention of ventilator-
associated pneumonia.4,5 Although several studies 
have identified the pivotal role of oropharyngeal 
colonization in the pathogenesis of ventilator-
associated pneumonia11,12 and the efficacy of SOD 
in preventing ventilator-associated pneumonia ap-
pears to be similar to the efficacy of SDD,13,14 a 
head-to-head comparison of the two strategies is 
needed. Because of methodologic issues,15,16 such 
as single-center study designs with limited gen-
eralizability, and concern about increased selec-
tion of antibiotic-resistant pathogens,17,18 the 
routine use of SDD and SOD has remained con-
troversial and has not been recommended in in-
ternational guidelines.19,20
Me thods
Study Design
We performed a controlled, crossover study using 
cluster randomization in 13 ICUs between May 
2004 and July 2006. The participating ICUs dif-
fered in size and teaching status, reflecting all 
levels of intensive care in the Netherlands. (More 
information on the ICUs can be found in the Sup-
plementary Appendix, available with the full text 
of this article at NEJM.org.) Since the interven-
tions included ecologic changes in the ICU, an 
individualized, randomized design would have al-
lowed the treatment of a patient in one study 
group to influence the treatment of a patient in 
another group. Therefore, cluster randomization 
was used, and all three study regimens (SDD, SOD, 
and standard care) were administered to all eli-
gible patients over the course of 6 months, with 
the order of regimens randomly assigned. A cross-
over design was used to control for unit-specific 
characteristics. Randomization was performed by 
a clinical pharmacist who was not involved in 
patient care in any of the participating units and 
who was unaware of the identity of each ICU. The 
order in which the regimens were assigned was 
randomly generated by computer software (De-
sign, version 2.0, a Systat Module), with alloca-
tion to the wards in consecutive order of study 
start. Study periods were preceded by washout and 
wash-in periods (for more information see the 
Supplementary Appendix). The antibiotics used 
were purchased by the hospitals. All authors vouch 
for the completeness and accuracy of the data 
presented.
Patients admitted to the ICU with an expected 
duration of mechanical ventilation of more than 
48 hours or an anticipated ICU stay of more than 
72 hours were eligible. Eligibility was assessed by 
physicians responsible for patient care in each unit. 
Pregnant patients and patients with documented 
or presumed allergy to any component of the anti-
microbial study regimens were excluded.
The study protocol was approved by the insti-
tutional review board at each participating hos-
pital. After reviewing the protocol, the boards 
waived the requirement for informed consent. Per-
mission to use patient-specific medical data for 
analysis was obtained from patients or their rep-
resentatives.
Inclusion rates were determined for each ICU 
and each study period. Research nurses visited 
each center regularly (at least twice per study pe-
riod) and evaluated up to 50 consecutively admit-
ted patients per visit (starting from a randomly 
chosen date) for eligibility and study inclusion.
The SDD regimen, which consisted of 4 days 
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of intravenous cefotaxime and topical application 
of tobramycin, colistin, and amphotericin B in the 
oropharynx and stomach, was identical to the 
regimen used by de Jonge et al.2 (for more infor-
mation see the Supplementary Appendix). The use 
of antibiotics with antianaerobic activity, such as 
amoxicillin, penicillin, amoxicillin–clavulanic acid, 
and carbapenems, was discouraged during the 
SDD period. Surveillance cultures of endotracheal 
aspirates and oropharyngeal and rectal swabs were 
obtained on admission and twice weekly there-
after.
SOD consisted of oropharyngeal application of 
the same paste used for SDD, with surveillance 
cultures of endotracheal aspirates and oropharyn-
geal swabs obtained on admission and twice 
weekly thereafter; there were no restrictions on 
physicians’ choices of systemic antibiotic therapy. 
During the period of standard care, no surveil-
lance cultures were obtained from patients, and 
there were no restrictions on physicians’ choices 
of systemic antibiotic therapy.
Antibiotic resistance was monitored with the 
use of point-prevalence studies on the third Tues-
day of each month. On these days, rectal swabs 
and endotracheal aspirates or throat swabs for 
surveillance cultures were obtained from all ICU 
patients, whether or not they were included in 
the study. The prevalence of specific pathogen-
resistance combinations was determined. (Details 
on the processing of surveillance cultures during 
SDD and SOD and on the monthly point-preva-
lence studies are available in the Supplementary 
Appendix.)
Approaches to infection control (other than the 
regimens being studied) did not change during 
the period of the study in any of the ICUs. (Oropha-
ryngeal care is described in the Supplementary 
Appendix.)
Statistical Analysis
The original analysis plan, which specified in-
hospital death  as the primary end point, did not 
take into account analysis of cluster effects and 
failed to specify how to address imbalances in 
baseline characteristics between study groups. 
However, the study design did not preclude post-
randomization selection bias.21 It was subsequent-
ly recognized that such an analysis plan failed to 
conform to the Consolidated Standards for the 
Reporting of Trials (CONSORT) guidelines for 
reporting cluster-randomization trials.22 Failure 
to account for cluster effects (e.g., with the use of 
a random-effects model) would have increased 
the chance of reporting spuriously significant find-
ings, and in the event of selection bias, failure to 
adjust for baseline characteristics could have led 
to bias in either direction.21,23 When confronted 
with these problems, we consulted a panel of ex-
perts in the field of clinical epidemiology and 
data analysis with no prior involvement in the 
study and no knowledge of outcome data. The 
panel unanimously recommended a revised anal-
ysis plan that overcame these problems. This plan 
specified mortality at day 28 as the primary end 
point (because it was thought that knowledge of 
the intervention being applied at any given time 
could have influenced discharge policies, compro-
mising the reliability of hospital discharge as an 
end point) and the use of a random-effects logis-
tic-regression model to adjust for all available 
covariates (the score on the Acute Physiology and 
Chronic Health Evaluation [APACHE II], intuba-
tion status, medical specialty [classified as surgical 
or other], age, and sex). 
This plan was adopted, with no further revi-
sions, and day 28 mortality data were subsequent-
ly collected through hospital and government sys-
tems (these data had not been available when the 
analysis plan was formulated). In-hospital mortal-
ity, prevalence of antibiotic resistance, and dura-
tion of mechanical ventilation, ICU stay, and hos-
pital stay for surviving patients were secondary 
end points. (Details on the power calculation and 
statistical analysis of secondary end points are 
available in the Supplementary Appendix.)
R esult s
Characteristics of the Patients
From May 2004 through July 2006, a total of 5939 
patients were enrolled in 13 participating cen-
ters: 1990 received standard care, 1904 received 
SOD, and 2045 received SDD. Permission for use 
of patient-specific medical data could not be ob-
tained for 12 patients (11 in the SDD group and 
1 in the standard-care group), who were excluded 
from all analyses except those for unadjusted mor-
tality; 44 patients were discharged alive from the 
hospital but were lost to follow-up at day 28. Over-
all, 48 patients crossed over to a subsequent study 
period. The total number of patients included in 
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Table 1. Baseline Characteristics of the Patients.*
Characteristic
SDD 
(N = 2045)
SOD 
(N = 1904)
Standard Care 
(N = 1990) P Value
 
SDD vs.  
Standard Care
SOD vs. 
 Standard Care
SDD vs.  
SOD
Age — yr† 62.4±15.9 61.4±16.3 61.4±16.2 0.04 0.88 0.05
Male sex — no. (%) 1244 (61.2) 1213 (63.7) 1220 (61.3) 0.90 0.13 0.09
Mean APACHE II score 19.6±7.8 19.5±8.2 18.6±7.9 0.00 0.001 0.63
APACHE II score ≥20 — no. (%) 969 (47.4) 897 (47.1) 837 (42.1) 0.001 0.002 0.87
Mechanical ventilation — no.(%) 1890 (92.9) 1793 (94.2) 1753 (88.1) 0.00 0.00 0.12
Reason for admission — no. (%)
Surgical 923 (45.4) 866 (45.5) 973 (48.9) 0.03 0.03 0.95
Medical 1111 (54.6) 1038 (54.5) 1016 (51.1) 
Specialty of admitting physician —  
no. (%)
Surgery 605 (29.7) 551 (28.9) 609 (30.6) 0.56 0.26 0.60
Cardiothoracic surgery 353 (17.4) 284 (14.9) 321 (16.1) 0.31 0.31 0.04
Neurosurgery 105 (5.2) 140 (7.4) 145 (7.3) 0.006 0.95 0.005
Neurology 124 (6.1) 144 (7.6) 128 (6.4) 0.70 0.19 0.08
Internal medicine 382 (18.8) 371 (19.5) 393 (19.8) 0.45 0.84 0.60
Cardiology 159 (7.8) 147 (7.7) 129 (6.5) 0.11 0.13 0.95
Pulmonology 152 (7.5) 138 (7.2) 127 (6.4) 0.19 0.31 0.81
Other 153 (7.5) 126 (6.6) 137 (6.9) 0.47 0.75 0.29
Unknown 1 (<1) 3 (0.2) 0 1.00 0.12 0.36
Previous or preexisting condition —  
no. (%)
Cardiovascular disease 1031 (50.7) 899 (47.2) 976 (49.1) 0.31 0.25 0.03
Pulmonary disease 530 (26.1) 448 (23.5) 489 (24.6) 0.29 0.45 0.07
Diabetes mellitus 281 (13.8) 274 (14.4) 302 (15.2) 0.23 0.50 0.61
Chronic renal insufficiency 155 (7.6) 135 (7.1) 119 (6.0) 0.05 0.17 0.54
Malignant solid tumor 220 (10.8) 193 (10.1) 196 (9.9) 0.33 0.79 0.50
Metastasized cancer 71 (3.5) 56 (2.9) 64 (3.2) 0.66 0.64 0.37
Hematologic cancer 56 (2.8) 51 (2.7) 48 (2.4) 0.55 0.61 0.92
Immunodepression or AIDS 60 (2.9) 47 (2.5) 47 (2.4) 0.28 0.84 0.38
Alcohol or drug abuse 112 (5.5) 120 (6.3) 111 (5.6) 0.95 0.34 0.31
Place from which patient was admitted 
to ICU — no. (%)
Emergency room 509 (25.0) 475 (24.9) 465 (23.4) 0.23 0.26 0.97
Other ICU 135 (6.6) 121 (6.4) 116 (5.8) 0.30 0.50 0.75
Hospital ward 961 (47.2) 915 (48.1) 943 (47.4) 0.80 0.80 1.00
Other 440 (21.5) 393 (20.5) 466 (23.4) 0.11 0.21 0.77
* Plus–minus values are means ±SD. Permission for use of patient-specific data could not be obtained for 11 patients in the selective diges-
tive tract decontamination (SDD) group and 1 patient in the standard-care group. AIDS denotes acquired immunodeficiency syndrome, 
APACHE Acute Physiology and Chronic Health Evaluation, and SOD selective oropharyngeal decontamination.
† Values for age are based on age at the time of hospital admission. 
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the study per center ranged from 119 in a 4-bed 
ICU in a nonteaching hospital to 1013 patients in 
a 43-bed ICU in a university hospital. (Details on 
patient enrollment per center are available in the 
Supplementary Appendix.)
Eligibility was determined for a total of 6565 
ICU admissions (with 300 to 1518 patients screened 
for eligibility per center). The average proportion 
of ICU patients eligible for study inclusion per 
center was 29.5% and ranged from 16.3 to 51.8%. 
Patients who were not eligible for the study had 
short ICU stays, in most cases after elective sur-
gery. Of all eligible patients, 89.2% were included. 
Inclusion rates ranged from 51.8 to 100% per cen-
ter. The mean inclusion rates for the SDD, SOD, 
and standard-care periods were 89.1%, 86.9%, 
and 91.6%, respectively (P = 0.03 for standard care 
vs. SOD, P>0.05 for the other comparisons), and 
rates for the first, second, and third periods were 
88.5%, 86.6%, and 92.8%, respectively (P = 0.02 
for the first period vs. the third period, P>0.05 for 
the other comparisons).
There were differences in baseline characteris-
tics between patients in the standard-care group 
and those in the SOD and SDD groups (Table 1). 
Patients who received standard care had slightly 
lower APACHE II scores, were less likely to be re-
ceiving mechanical ventilation, and were more 
likely to have been admitted for surgical reasons. 
The proportions of patients who received antibi-
otics before admission to the ICU were similar 
in all three study groups. In the SOD and SDD 
groups, medication was administered according 
to protocol on 95.7% and 97.5% of all patient-
days, respectively. Noncompliance, which was most 
frequent at the end of the ICU stay, was most 
often due to the patient’s decision to decline med-
ication.
Primary and Secondary Clinical End Points
Crude mortality at day 28 for patients in the stan-
dard-care, SOD, and SDD groups was 27.5%, 26.6%, 
and 26.9%, respectively. In a random-effects lo-
gistic-regression model adjusted for age, sex, 
APACHE II score, intubation status, medical spe-
cialty, study site, and study period, odds ratios 
for death during the first 28 days for the SOD 
and SDD groups, as compared with the standard-
care group, were 0.86 (95% confidence interval 
[CI], 0.74 to 0.99; P = 0.045) and 0.83 (95% CI, 0.72 
to 0.97; P = 0.02), respectively (Table 2). When co-
variates were added to the model one at a time in 
order of statistical significance, it was evident 
that those with significant imbalances had the 
largest effect on the odds ratio (for more infor-
mation see the Supplementary Appendix). The in-
tracluster correlation coefficient was 0.010. With 
a baseline rate of death during the first 28 days 
of 27.5%, absolute and relative reductions in mor-
tality at day 28 were 3.5% and 13%, respectively, 
for the SDD group and 2.9% and 11%, respec-
tively, for the SOD group, corresponding with the 
needed-to-treat numbers of 29 and 34 to prevent 
one casualty at day 28 for SDD and SOD, respec-
Table 3. Cumulative Incidence of ICU-Acquired Bacteremia and Candidemia.*
Type of Infection Study Group Crude Odds Ratio (95% CI)
Standard Care 
(N = 1990)
SOD 
(N = 1904)
SDD 
(N = 2045)
SDD vs. Standard 
Care
SOD vs. Standard 
Care SDD vs. SOD
no. (%)
Staphylococcus aureus 22 (1.1) 9 (0.5) 9 (0.4) 0.40 (0.18–0.86) 0.43 (0.20–0.93) 0.93 (0.37–2.40)
Streptococcus pneumoniae 3 (0.2) 1 (0.1) 1 (0.0) 0.32 (0.03–3.12) 0.35 (0.04–3.35)  0.93 (0.06–14.90)
GNF-GNR species† 36 (1.8) 17 (0.9) 16 (0.8) 0.43 (0.24–0.77) 0.49 (0.27–0.87) 0.88 (0.44–1.74)
Enterobacteriaceae 87 (4.4) 59 (3.1) 18 (0.9) 0.19 (0.12–0.32) 0.70 (0.50–0.98) 0.28 (0.16–0.47)
Enterococcus species 55 (2.8) 49 (2.6) 48 (2.3) 0.85 (0.57–1.25) 0.93 (0.63–1.37) 0.91 (0.61–1.36)
Candida species 16 (0.8) 14 (0.7) 8 (0.4) 0.49 (0.21–1.11) 0.91 (0.45–1.85) 0.53 (0.23–1.24)
Patients with at least one episode  
of bacteremia or candidemia — 
no. (%)
186 (9.3) 124 (6.5) 88 (4.3) 0.44 (0.34–0.57) 0.68 (0.53–0.86) 0.65 (0.49–0.85)
* SDD denotes selective digestive tract decontamination, and SOD selective oropharyngeal decontamination.
† Glucose-nonfermenting gram-negative rods (GNF-GNR) are characteristic of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and 
acinetobacter species.
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tively. There was a tendency for SDD and SOD to 
be associated with reductions in durations of me-
chanical ventilation, ICU stay, and hospital stay 
(Table 2). There was no evidence of an association 
of temporal trends, autocorrelation, or period-level 
effects with primary or secondary end points.
Microbiologic Findings
Among patients receiving SDD or SOD as com-
pared with those receiving standard care, crude 
incidences of ICU-acquired bacteremia were sig-
nificantly reduced for S. aureus, glucose-nonfer-
menting gram-negative rods (mainly Pseudomonas 
aeruginosa), and Enterobacteriaceae (Table 3). Pa-
tients receiving SDD had a lower incidence of 
ICU-acquired bacteremia with Enterobacteriaceae 
than did those receiving SOD. The incidence of 
ICU-acquired candidemia tended to be lower in 
the SDD group than in either the SOD group or 
the standard-care group, although the difference 
was not significant. No significant differences 
among the three study groups were observed for 
infection with Streptococcus pneumoniae or Entero-
coccus species. Clostridium difficile toxin was detected 
in 15 patients (0.8%) in the standard-care group, 
5 patients (0.3%) in the SOD group, and 9 patients 
(0.4%) in the SDD group.
The estimated completeness of surveillance 
cultures per center was, on average, 87% (range, 
70 to 97) for respiratory tract samples and 87% 
(range, 62 to 100) for rectal samples. The rate of 
isolation of gram-negative bacteria from rectal 
swabs among patients receiving SDD was reduced 
from 56% at day 3 to 25% at day 8 and 15% at 
day 14 (Fig. 1). The rate of culture positivity for 
gram-negative bacteria in oropharyngeal swabs 
from patients receiving SDD ranged from 18% at 
day 2 to 4% at day 8. Among patients treated with 
SOD, culture positivity ranged from 20% at day 
2 to 7% at day 8 (Fig. 1).
In all, 2596 patients were included in the 
monthly point-prevalence surveillance studies for 
respiratory tract colonization (894 in the SDD 
group, 811 in the SOD group, and 891 in the 
standard-care group), and 2963 patients were in-
cluded in the analysis of rectal colonization (988 
in the SDD group, 947 in the SOD group, and 1028 
in the standard-care group). Estimated complete-
ness of culture surveillance per center was, on 
average, 87% (range, 67 to 98) for rectal samples 
and 82% (range, 69 to 95) for respiratory tract 
samples. The data from six point-prevalence mea-
surements per study period were analyzed together. 
For all pathogen–antibiotic combinations, the rate 
of nonsusceptibility was less than 5% (Table 4). 
For multidrug resistance, the rate of nonsuscep-
33p9
60
G
ra
m
-N
eg
at
iv
e 
B
ac
te
ri
a
(%
 o
f p
at
ie
nt
s)
40
30
10
50
20
0
1 2 3 4 5 6 7 8 9 10 11 12 13 14 Wk 3 Wk 4
Days
AUTHOR:
FIGURE:
JOB:
4-C
H/T
RETAKE
SIZE
ICM
CASE
EMail Line
H/T
Combo
Revised
AUTHOR, PLEASE NOTE: 
Figure has been redrawn and type has been reset.
Please check carefully.
REG F
Enon
1st
2nd
3rd
De Smet
1 of 1
01-01-09
ARTIST: ts
36001 ISSUE:
SDD — rectal
colonization
SDD — oropharyngeal
carriage
SOD — oropharyngeal
carriage
Figure 1. Detection of Gram-Negative Bacteria in Patients in the Intensive Care Unit Who Were Treated  
with Selective Digestive Tract Decontamination (SDD) or Selective Oropharyngeal Decontamination (SOD).
The New England Journal of Medicine 
Downloaded from nejm.org at RADBOUD UNIVERSITEIT NIJMEGEN on July 13, 2012. For personal use only. No other uses without permission. 
 Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
Decontamination of the Digestive Tr act and Oropharynx in ICU Patients
n engl j med 360;1 nejm.org january 1, 2009 27
Ta
bl
e 
4.
 D
et
ec
tio
n 
of
 A
nt
ib
io
tic
-R
es
is
ta
nt
, G
ra
m
-N
eg
at
iv
e 
B
ac
te
ri
a 
in
 R
ec
ta
l a
nd
 R
es
pi
ra
to
ry
 T
ra
ct
 S
am
pl
es
 d
ur
in
g 
Po
in
t-
Pr
ev
al
en
ce
 S
ur
ve
ys
.*
O
rg
an
is
m
R
es
is
ta
nt
 t
o 
A
m
in
og
ly
co
si
de
s†
R
es
is
ta
nt
 t
o 
C
ip
ro
flo
xa
ci
n
R
es
is
ta
nt
 t
o 
C
ef
ta
zi
di
m
e
M
ul
tir
es
is
ta
nt
 A
‡
M
ul
tir
es
is
ta
nt
 B
§
St
an
da
rd
 
C
ar
e
SO
D
SD
D
St
an
da
rd
 
C
ar
e
SO
D
SD
D
St
an
da
rd
 
C
ar
e
SO
D
SD
D
St
an
da
rd
 
C
ar
e
SO
D
SD
D
St
an
da
rd
  
C
ar
e
SO
D
SD
D
pe
rc
en
ta
ge
 o
f p
at
ie
nt
s
R
ec
ta
l s
am
pl
es
Es
ch
er
ic
hi
a 
co
li
4.
5¶
4.
9¶
1.
8
4.
9¶
4.
5
2.
9
3.
3¶
2.
3
1.
3
2.
2¶
2.
3¶
0.
5
1.
4
1.
0
0.
5
K
le
bs
ie
lla
 p
ne
um
on
ia
e
2.
6¶
1.
4
1.
0
3.
0¶
‖
1.
4
0.
7
2.
2¶
1.
1
0.
4
0.
6
1.
0
0.
6
1.
9¶
‖
0.
3
0.
3
En
te
ro
ba
ct
er
 c
lo
ac
ae
1.
7¶
1.
8¶
0.
6
1.
3
1.
6
0.
5
4.
7¶
4.
2¶
1.
7
1.
0
1.
1
0.
5
0.
6
1.
0
0.
2
Ps
eu
do
m
on
as
 a
er
ug
in
os
a
1.
2
1.
0
0.
7
1.
6
1.
6
0.
7
2.
6¶
1.
8¶
0.
7
1.
3¶
0.
8
0.
4
0.
4
0.
3
0.
4
R
es
pi
ra
to
ry
 tr
ac
t s
am
pl
es
E.
 c
ol
i
1.
3¶
0.
5
0
1.
0
0.
2
0.
4
1.
0¶
0.
5
0
0.
4
0.
1
0
0.
4
0.
2
0
K
. p
ne
um
on
ia
e
2.
0¶
‖
0.
5
0.
2
2.
4¶
‖
0.
4
0.
2
1.
9¶
‖
0.
6
0.
2
0.
1
0.
2
0.
1
2.
0
0.
2
0.
1
E.
 c
lo
ac
ae
1.
5¶
0.
5
0.
4
1.
1‖
0.
2
0.
4
3.
8¶
‖
0.
6
1.
2
0.
6
0.
2
0
0.
6
0.
1
0.
3
P.
 a
er
ug
in
os
a
2.
6¶
1.
8
1.
0
3.
7¶
‖
1.
8
0.
9
3.
5¶
‖
1.
1
0.
4
2.
2
1.
2
0.
4
0.
8
0.
1
0.
1
* 
Th
e 
to
ta
l n
um
be
r 
of
 r
ec
ta
l s
am
pl
es
 a
nd
 t
he
 m
ea
n 
(±
SD
) 
nu
m
be
r 
of
 p
at
ie
nt
s 
fr
om
 w
ho
m
 t
he
y 
w
er
e 
ob
ta
in
ed
 d
ur
in
g 
th
e 
si
x 
po
in
t-
pr
ev
al
en
ce
 s
ur
ve
ys
 w
er
e 
as
 fo
llo
w
s 
fo
r 
th
e 
th
re
e 
st
ud
y 
gr
ou
ps
: s
ta
nd
ar
d 
ca
re
, 1
02
8 
sa
m
pl
es
 fr
om
 1
71
±1
3 
pa
tie
nt
s;
 s
el
ec
tiv
e 
or
op
ha
ry
ng
ea
l d
ec
on
ta
m
in
at
io
n 
(S
O
D
),
 9
47
 s
am
pl
es
 fr
om
 1
58
±1
1 
pa
tie
nt
s;
 a
nd
 s
el
ec
tiv
e 
di
ge
st
iv
e 
tr
ac
t 
de
co
n-
ta
m
in
at
io
n 
(S
D
D
),
 9
88
 s
am
pl
es
 fr
om
 1
65
±8
 p
at
ie
nt
s.
 T
he
 t
ot
al
 n
um
be
r 
of
 r
es
pi
ra
to
ry
 s
am
pl
es
 a
nd
 t
he
 m
ea
n 
nu
m
be
r 
of
 p
at
ie
nt
s 
w
er
e 
as
 fo
llo
w
s:
 s
ta
nd
ar
d 
ca
re
, 8
91
 s
am
pl
es
 fr
om
 
14
9±
3 
pa
tie
nt
s;
 S
O
D
, 1
1 
sa
m
pl
es
 fr
om
 1
35
±1
2 
pa
tie
nt
s;
 a
nd
 S
D
D
, 8
94
 s
am
pl
es
 fr
om
 1
49
±7
 p
at
ie
nt
s.
†
 T
he
 a
m
in
og
ly
co
si
de
s 
w
er
e 
ge
nt
am
ic
in
 a
nd
 t
ob
ra
m
yc
in
.
‡
 T
he
se
 b
ac
te
ri
a 
ar
e 
re
si
st
an
t 
to
 t
he
 a
m
in
og
ly
co
si
de
s 
ge
nt
am
ic
in
 a
nd
 t
ob
ra
m
yc
in
 a
nd
 t
o 
ci
pr
of
lo
xa
ci
n 
or
 c
ef
ta
zi
di
m
e.
§ 
Th
es
e 
ba
ct
er
ia
 a
re
 r
es
is
ta
nt
 t
o 
th
e 
am
in
og
ly
co
si
de
s 
ge
nt
am
ic
in
 a
nd
 t
ob
ra
m
yc
in
 a
nd
 t
o 
ci
pr
of
lo
xa
ci
n 
an
d 
ce
ft
az
id
im
e.
¶
 P
<0
.0
5 
fo
r 
th
e 
co
m
pa
ri
so
n 
w
ith
 S
D
D
.
‖ 
P<
0.
05
 fo
r 
th
e 
co
m
pa
ri
so
n 
w
ith
 S
O
D
.
The New England Journal of Medicine 
Downloaded from nejm.org at RADBOUD UNIVERSITEIT NIJMEGEN on July 13, 2012. For personal use only. No other uses without permission. 
 Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 360;1 nejm.org january 1, 200928
tibility was less than 2.5% for two antibiotics and 
less than or equal to 2% for three antibiotics. The 
proportion of patients with gram-negative bacte-
ria in rectal swabs that were not susceptible to the 
marker antibiotics was lower with SDD than with 
standard care or SOD (Table 4). The proportions 
of patients with nonsusceptible bacteria in respi-
ratory tract samples were similar in the SDD and 
SOD groups and were lower than the proportion 
in the standard-care group. There were no patients 
with methicillin-resistant S. aureus; eight patients 
had vancomycin-resistant enterococci in rectal 
swabs: six in the standard-care group (0.6%) and 
two in the SOD group (0.2%).
Antibiotic Use
The median number of defined daily doses of 
systemic antibiotic agents (including antifungal 
agents) per patient-day did not differ significant-
ly among the SDD, SOD, and standard-care peri-
ods: 0.72 (interquartile range, 0.44 to 1.33), 0.84 
(interquartile range, 0.25 to 1.58), and 0.84 (in-
terquartile range, 0.29 to 1.55), respectively. Dur-
ing treatment with SDD as compared with stan-
dard care, the use of antimicrobial agents with 
antianaerobic activity was reduced by 27.8% for 
broad-spectrum penicillins, 45.7% for carbapen-
ems, and 11.6% for lincosamides (Table 5). Fur-
thermore, quinolone use (mainly ciprofloxacin) 
was reduced by 31.4%. In contrast, systemic use of 
cephalosporins increased by 86.6%. There were 
less pronounced differences in antibiotic use be-
tween the SOD group and the standard-care 
group (Table 5). Total defined daily doses were 
11.9% and 10.1% lower with SDD and SOD, re-
spectively, than with standard care.
Adverse Events
In one patient receiving SDD, esophageal obstruc-
tion developed as a result of clotted oropharyn-
geal medication, which was removed through en-
doscopy.24
Discussion
These data show an absolute reduction in mor-
tality of 3.5 and 2.9 percentage points (corre-
sponding to relative reductions of 13% and 11%) 
at day 28 with SDD and SOD, respectively, among 
patients admitted to Dutch ICUs. Patients were 
treated with topical components at a cost per day 
of $1 for SOD and $12 for SDD, without evidence 
of the emergence of antibiotic-resistant patho-
gens or increased rates of detection of C. difficile 
toxin (at least during the relatively short period of 
study). This benefit was discernible only after ad-
justment for covariates. The overall study period 
was not long enough to evaluate the effect of the 
prophylactic regimens on microbial flora.
The strengths of the study include its prag-
matic, multicenter, crossover design and the mon-
itoring of inclusion rates. Overall, an estimated 
89% of eligible patients were included. Cluster 
randomization was needed to avoid the possibil-
ity that one study regimen would influence the 
outcome of another regimen. A consequence of 
this study design is the absence of concealment 
of randomization. Although randomized treatment 
Table 5. Antibiotic Use.*
Antibiotic SDD SOD Standard Care
No. of Defined 
Daily Doses
Percent Change 
 (vs. Standard Care)
No. of Defined 
Daily Doses 
Percent Change 
(vs. Standard Care)
No. of Defined  
Daily Doses 
Penicillins 9,767 −27.8 12,805 −5.3 13,523
Carbapenems 724 −45.7 995 −25.4 1,334
Cephalosporins 8,473 +86.6 3,935 −13.3 4,541
Quinolones 2,637 −31.4 3,291 −14.4 3,846
Lincosamides 473 −11.6 553 +3.4 535
Other antibiotics 7,589 −23.4 8,720 −12.0 9,909
All systemic antibiotics 29,663 −11.9 30,299 −10.1 33,688
* SDD denotes selective digestive tract decontamination, and SOD selective oropharyngeal decontamination.
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assignments for study periods were concealed, 
the actual inclusion of patients was not random-
ized, and the physicians responsible for patient 
inclusion were aware of the assigned intervention. 
Blinding of physicians (or having a third person, 
who was unaware of the assigned interventions, 
overseeing inclusion) was deemed impossible. To 
minimize the risk of selection bias due to differ-
ences in patient inclusion among study centers and 
during different study periods, inclusion rates 
were monitored frequently for any instances of 
selective inclusion. Nevertheless, despite the use 
of objective inclusion criteria and the provision of 
continual feedback on inclusion rates to the par-
ticipating centers, baseline differences were pres-
ent between the standard-care group and both 
intervention groups, with patients in the interven-
tion groups tending to be older, more likely to be 
intubated, and less likely to be surgical patients 
and tending to have a higher baseline APACHE II 
score. These differences were not consistent with 
chance, and they account for the differences be-
tween the crude and adjusted outcomes (Table 2).
The microbiologic aims of treatment with SDD 
or SOD were achieved in this study. During the 
SDD periods, all patients received intravenous pro-
phylaxis with cefotaxime, and the desired micro-
biologic effects on carriage of gram-negative bac-
teria in the respiratory and intestinal tracts were 
achieved. Rates of eradication of gram-negative 
bacteria in the intestines and oropharynx were 
slightly higher than those reported by Stouten-
beek et al.7 and others.25,26 During the SDD and 
SOD study periods, prevalence rates for antibiotic-
resistant gram-negative bacteria were lower than 
they were during the standard-care periods. These 
results are consistent with the finding, reported 
by de Jonge et al.2 and others,27,28 that in settings 
with low levels of circulating antibiotic-resistant 
organisms, SDD is not associated with increased 
selection or induction of antibiotic resistance in 
the short term. However, in settings with high 
levels of endemic, multidrug-resistant gram-neg-
ative bacteria17,29 or methicillin-resistant S. au-
reus,18 SDD was associated with increased selec-
tion of such pathogens.
A limitation of our study is that the original 
analysis plan was not appropriate for the study 
design. Although analyses similar to that origi-
nally proposed have been widely used to assess 
data from cluster-randomization trials, they in-
crease the chance of incorrect inferences. Conclu-
sions based on such analyses cannot be consid-
ered reliable.21,22 Faced with the choice between 
performing an analysis known to be inappropri-
ate and creating a new analysis plan, we decided 
that the latter was preferable. Very similar con-
clusions about the interventions would have 
been reached had the primary outcome been in-
hospital mortality, as originally planned (with 
SDD very slightly less effective than SOD), after 
adjustment for baseline imbalances (Table 2). 
Evidence for the effectiveness of the interven-
tions is supported by the significant reductions 
in the incidence of ICU-acquired bacteremia for 
important nosocomial pathogens in both inter-
vention groups. Of note, the multiple compari-
sons of standard care with SDD and SOD in-
crease the likelihood of type I errors.
Our finding that SDD and SOD have similar 
effects on survival raises questions about the 
relevance of systemic therapy with cefotaxime 
during the first 4 days of gastric and intestinal 
decontamination. Considering the importance of 
antibiotic resistance in ICUs, the SOD regimen 
seems preferable to the SDD regimen because it 
does not include widespread systemic prophylaxis 
with cephalosporins and involves a lower volume 
of topical antibiotics, thus minimizing the risk of 
selection for and development of antibiotic resis-
tance in the long term. Furthermore, oropharyn-
geal decontamination with antiseptic agents, such 
as chlorhexidine, might be an alternative in en-
vironments with high levels of antibiotic resis-
tance.13,30,31
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